Neurology
-
Randomized Controlled Trial Multicenter Study
Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein neuropathy.
To determine whether rituximab 375 mg/m(2) was efficacious in patients with immunoglobulin M (IgM) anti-myelin-associated glycoprotein antibody demyelinating neuropathy (IgM anti-MAG demyelinating neuropathy). ⋯ This study provides Class I evidence that rituximab is ineffective in improving ISS in patients with IgM anti-MAG demyelinating neuropathy.